Frank Tomaka

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Dan H. Barouch, Frank Tomaka, Frank Wegmann et al. · The Lancet · 2018 · 342 citations

Veterinary Medicine, Immunology, Infectious Diseases +13

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

José Valdez Madruga, Daniel Berger, Marilyn McMurchie et al. · The Lancet · 2007 · 332 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

Pedro Cahn, Jan Fourie, Beatriz Grinsztejn et al. · AIDS · 2011 · 114 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

Lindsey R. Baden, Daniel J Stieh, Michal Sarnecki et al. · The Lancet HIV · 2020 · 91 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96

Keikawus Arastéh, Patrick Yéni, Anton Pozniak et al. · Antiviral Therapy · 2009 · 83 citations

Pharmacy, Pharmacology, Pharmacotherapy +17